Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 6/20 | 0.59 |
| ▸ | NT5E | P21589 | 1/20 | 0.54 |
| ▸ | GSK3A | P49840 | 2/20 | 0.53 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.53 |
| ▸ | PNP | P00491 | 1/20 | 0.51 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | KRAS | P01116 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL237754 | 0.82 | HINT1 (0.58) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL16555277 | 0.81 | HINT1 (0.55) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL217117 | 0.81 | HINT1 (0.80) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL313550 | 0.81 | AHCY (0.60) | — | |
| SCHEMBL12813018 | 0.79 | DNMT1 (0.57) | HINT1 | |
| SCHEMBL1506529 | 0.79 | NT5E (0.56) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| Guanosine SCHEMBL30289937 | 0.79 | HPGD (0.69) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL24299397 | 0.78 | HINT1 (0.62) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL13833323 | 0.78 | HINT1 (0.62) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL4278130 | 0.78 | HINT1 (0.62) | HINT1NT5EGSK3ARPS6KA3MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102485738-A | Synthetic method of | LIANYUNGANG SHENGHE BIOTECHNOLOGY CO LTD | 2012-06-06 | — | — | CN | claimed |
| EP-0827960-A1 | Process for producing purine derivatives | Ajinomoto Co., Inc. (JP) | 1998-03-11 | — | — | EP | claimed |
| JP-10087664-A | — | — | None | — | — | JP | disclosed |
| US-20250171482-A1 | DEACYLATION OF CARBOHYDRATE COMPOUNDS | UNIVERSITY OF SOUTH ALABAMA | 2025-05-29 | — | — | US | disclosed |
| CN-118632856-A | By bringing the carbohydrate deacylation of the substance | 益力舒健康公司 | 2024-09-10 | — | — | CN | disclosed |
| WO-2023178017-A1 | DEACYLATION OF CARBOHYDRATE COMPOUNDS | ELYSIUM HEALTH INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20180066009-A1 | Nucleosides and Oligonucleotides for Studies on Reversal of Cytotoxic and Mutagenic Damage of DNA and as Diagnostics Tools | CHEMGENES CORP (US) | 2018-03-08 | — | — | US | disclosed |
| US-9718855-B2 | Nucleosides and oligonucleotides for studies on reversal of cytotoxic and mutagenic damage of DNA and as diagnostics tools | CHEMGENES CORPORATION (US) | 2017-08-01 | — | — | US | disclosed |
| US-20140350234-A1 | Nucleosides and Oligonucleotides for Studies on Reversal of Cytotoxic and Mutagenic Damage of DNA and as Diagnostics Tools | CHEMGENES CORPORATION (US) | 2014-11-27 | — | — | US | disclosed |
| US-8785619-B1 | Nucleosides and oligonucleotides for studies on reversal of cytotoxic and mutagenic damage of DNA potential diagnostics tools | CHEMGENES CORPORATION (US) | 2014-07-22 | — | — | US | disclosed |
| CN-101830955-B | Synthesizing process of antineoplastic agent clofarabine | ZHEJIANG HISUN PHARM CO LTD | 2013-09-11 | — | — | CN | disclosed |
| JP-H1087664-A | PRODUCTION OF PURINE DERIVATIVE | AJINOMOTO CO INC | 1998-04-07 | — | — | JP | disclosed |
| EP-0827960-A1 | Process for producing purine derivatives | Ajinomoto Co., Inc. (JP) | 1998-03-11 | — | — | EP | disclosed |
| EP-0771204-A1 | METHODS FOR TREATING SEPSIS OR INFLAMMATORY DISEASES WITH OXYPURINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1997-05-07 | — | — | EP | disclosed |
| WO-1996004923-A1 | METHODS FOR TREATING SEPSIS OR INFLAMMATORY DISEASES WITH OXYPURINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1996-02-22 | — | — | WO | disclosed |
| EP-0570519-A4 | OXYPURINE NUCLEOSIDES AND THEIR CONGENERS, AND ACYL DERIVATIVES THEREOF, FOR IMPROVEMENT OF HEMATOPOIESIS | PRO NEURON INC (US) | 1996-02-21 | — | — | EP | disclosed |
| EP-0570519-A1 | OXYPURINE NUCLEOSIDES AND THEIR CONGENERS, AND ACYL DERIVATIVES THEREOF, FOR IMPROVEMENT OF HEMATOPOIESIS | PRO-NEURON, INC. (US) | 1993-11-24 | — | — | EP | disclosed |
| WO-1992013561-A1 | OXYPURINE NUCLEOSIDES AND THEIR CONGENERS, AND ACYL DERIVATIVES THEREOF, FOR IMPROVEMENT OF HEMATOPOIESIS | PRO-NEURON, INC. (US) | 1992-08-20 | — | — | WO | disclosed |
| EP-0269574-A2 | Novel adenosine derivatives and pharmaceutical compositions containing them as an active ingredient | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1988-06-01 | — | — | EP | disclosed |
| EP-0191624-A2 | Gold-purine antitumor agents | ENGELHARD CORPORATION (US) | 1986-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171482-A1 | DEACYLATION OF CARBOHYDRATE COMPOUNDS | FUT5, DDOST, TREH | HINT1 1418/4885NT5E 2744/4885GSK3A 1444/4885 |
| US-20140350234-A1 | Nucleosides and Oligonucleotides for Studies on Reversal of Cytotoxic and Mutagenic Damage of DNA and as Diagnostics Tools | UNG, OGG1, ADAR | HINT1 295/4885NT5E 42/4885GSK3A 3436/4885 |
| US-20180066009-A1 | Nucleosides and Oligonucleotides for Studies on Reversal of Cytotoxic and Mutagenic Damage of DNA and as Diagnostics Tools | UNG, OGG1, ADAR | HINT1 295/4885NT5E 42/4885GSK3A 3436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.